<?xml version="1.0"?>


<!DOCTYPE rdf:RDF [
    <!ENTITY owl "http://www.w3.org/2002/07/owl#" >
    <!ENTITY obo "http://purl.obolibrary.org/obo/" >
    <!ENTITY dc "http://purl.org/dc/elements/1.1/" >
    <!ENTITY xsd "http://www.w3.org/2001/XMLSchema#" >
    <!ENTITY rdfs "http://www.w3.org/2000/01/rdf-schema#" >
    <!ENTITY rdf "http://www.w3.org/1999/02/22-rdf-syntax-ns#" >
]>


<rdf:RDF xmlns="&obo;dronx/"
     xml:base="&obo;dronx/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:owl="http://www.w3.org/2002/07/owl#"
     xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
     xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
     xmlns:obo="http://purl.obolibrary.org/obo/"
     xmlns:dc="http://purl.org/dc/elements/1.1/">
    <owl:Ontology rdf:about="&obo;dronx/">
        <dc:contributor>Caitrin McDonough Rowe</dc:contributor>
        <dc:contributor>Matthew Diller</dc:contributor>
        <owl:versionInfo>2017-03-22</owl:versionInfo>
        <rdfs:comment xml:lang="en">This ontology is an extension of the dron-lite.owl module from the Drug Ontology. It includes additional classes and DL axioms for several classes of anti-hypertensive drugs and their mechanisms of action.</rdfs:comment>
        <owl:imports rdf:resource="&obo;dron/dron-lite.owl"/>
    </owl:Ontology>
    


    <!-- 
    ///////////////////////////////////////////////////////////////////////////////////////
    //
    // Classes
    //
    ///////////////////////////////////////////////////////////////////////////////////////
     -->

    


    <!-- http://purl.obolibrary.org/obo/DRON_00005000 -->

    <owl:Class rdf:about="&obo;DRON_00005000">
        <rdfs:label xml:lang="en">function-inhibiting alpha-1-adrenergic receptor binding disposition</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000016"/>
        <obo:IAO_0000117>Caitrin McDonough Rowe</obo:IAO_0000117>
        <obo:IAO_0000115 xml:lang="en">A disposition of a molecule to bind to an instance of an alpha-1-adrenergic receptor in a manner that inhibits the realization of a function of the receptor instance.</obo:IAO_0000115>
        <obo:IAO_0000119 xml:lang="en">Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 12th Edition. Section II. Chapter 12 - Adrenergic Agonists and Antagonists.</obo:IAO_0000119>
        <obo:IAO_0000117>Matthew Diller</obo:IAO_0000117>
        <obo:IAO_0000118 xml:lang="en">alpha-1-adrenergic receptor antagonist</obo:IAO_0000118>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DRON_00005001 -->

    <owl:Class rdf:about="&obo;DRON_00005001">
        <rdfs:label xml:lang="en">function-inhibiting epithelial sodium channel binding disposition</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000016"/>
        <obo:IAO_0000115 xml:lang="en">A disposition of a molecule to bind to an instance of an epithelial sodium channel in a manner that inhibits the realization of a function of the sodium channel instance.</obo:IAO_0000115>
        <obo:IAO_0000117>Matthew Diller</obo:IAO_0000117>
        <obo:IAO_0000117>Caitrin McDonough Rowe</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 12th Edition. Section III. Chapter 25 - Antagonists of Mineralocorticoid Receptors (Aldosterone Antagonists, Potassium-Sparing Diuretics).</obo:IAO_0000119>
        <obo:IAO_0000118 xml:lang="en">function-inhibiting amiloride-sensitive sodium channel binding disposition</obo:IAO_0000118>
        <obo:IAO_0000118 xml:lang="en">potassium-sparing disposition</obo:IAO_0000118>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DRON_00005002 -->

    <owl:Class rdf:about="&obo;DRON_00005002">
        <rdfs:label xml:lang="en">function-inhibiting mineralocorticoid receptor binding disposition</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000016"/>
        <obo:IAO_0000117>Caitrin McDonough Rowe</obo:IAO_0000117>
        <obo:IAO_0000115 xml:lang="en">A disposition of a molecule to bind to an instance of a mineralocorticoid receptor in a manner that competitively inhibits the binding of an instance of aldosterone.</obo:IAO_0000115>
        <obo:IAO_0000117>Matthew Diller</obo:IAO_0000117>
        <obo:IAO_0000119 xml:lang="en">Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 12th Edition. Section III. Chapter 25 - Antagonists of Mineralocorticoid Receptors (Aldosterone Antagonists, Potassium-Sparing Diuretics).</obo:IAO_0000119>
        <obo:IAO_0000118 xml:lang="en">aldosterone antagonist</obo:IAO_0000118>
        <obo:IAO_0000118 xml:lang="en">function-competitive inhibition of mineralocorticoid receptor binding disposition</obo:IAO_0000118>
    </owl:Class>
    


    <!-- http://purl.obolibrary.org/obo/DRON_00005003 -->

    <owl:Class rdf:about="&obo;DRON_00005003">
        <rdfs:label xml:lang="en">function-inhibiting renin catalytic activity disposition</rdfs:label>
        <rdfs:subClassOf rdf:resource="&obo;BFO_0000016"/>
        <obo:IAO_0000117>Caitrin McDonough Rowe</obo:IAO_0000117>
        <obo:IAO_0000117>Matthew Diller</obo:IAO_0000117>
        <obo:IAO_0000115 xml:lang="en">A disposition of a molecule to directly and competitively inhibit the catalytic activity of an instance of renin in a manner that leads to diminished production of AngI (angiotensin I).</obo:IAO_0000115>
        <obo:IAO_0000119 xml:lang="en">Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 12th Edition. Section III. Chapter 27 - Direct Renin Inhibitors</obo:IAO_0000119>
        <obo:IAO_0000118 xml:lang="en">direct renin inhibitor</obo:IAO_0000118>
        <obo:IAO_0000118 xml:lang="en">function-direct and competitive inhibition of renin activity</obo:IAO_0000118>
    </owl:Class>
</rdf:RDF>



<!-- Generated by the OWL API (version 3.5.1) http://owlapi.sourceforge.net -->

